Nutrinia's new product receives FDA's orphan drug designation: 5 quick facts

Here are five quick facts:

1. The drug, NTRA-9620, is administered orally and it aims to help those suffering from short bowel syndrome.

2. It also aims to reduce patients’ dependence on parenteral nutrition.

3. The drug is intended to enhance post-resection bowel adaptation and improve patient outcomes.

4. The company will soon begin a clinical trial for the drug.

5. Nutrinia focuses on developing drug products to treat acute to chronic intestinal failure based on its proprietary insulin-based technology.

More articles on GI/endoscopy:
AGA launches IBS survey for patients, physicians
AGA launches IBS survey for patients, physicians
GI physician leader to know: Dr. John Popp of University of South Carolina School of Medicine

Next Up in GI & Endoscopy

GI procedure pay: What’s up, what’s down for the 5 most common services

Office-based endoscopy procedures would see an average 16% increase in Medicare payment in 2026, while ASCs and hospital outpatient departments…

Gastroenterology reimbursement cuts in 10 key stats

Gastroenterology reimbursement continues to erode under Medicare and commercial payment models, even as operating costs, staffing pressures and inflation rise.…

GI leaders name the biggest disruptors of 2026

From AI-assisted endoscopy and triage models to outpatient expansion, these are the disruptors gastroenterologists told Becker’s will define the specialty’s…

From denials to disruption: What 2026 will demand of health systems in a payer-driven market

Next Up in GI & Endoscopy

GI procedure pay: What’s up, what’s down for the 5 most common services

Gastroenterology reimbursement cuts in 10 key stats

GI leaders name the biggest disruptors of 2026

Join the 40,000+ ASC leaders who start their day with Becker's